SpringWorks Therapeutics Inc (NAS:SWTX)
$ 41.48 -0.25 (-0.6%) Market Cap: 3.09 Bil Enterprise Value: 2.72 Bil PE Ratio: 0 PB Ratio: 5.79 GF Score: 38/100

SpringWorks Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 03:30PM GMT
Release Date Price: $26.41 (-4.03%)
Anupam Rama
JPMorgan Chase & Co. - Analyst

Okay. Welcome, everyone, to the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my team, Malcolm Kuno and Priyanka Grover.

We're going to kick the conference off with the presentation from SpringWorks. And speaking on behalf of the company, we have CEO, Saqib Islam. Saqib?

Saqib Islam
SpringWorks Therapeutics, Inc. - CEO

Thank you, Anupam. It's a pleasure to be here, and we appreciate you hosting us again this year. Before we begin, I'll remind you that today's presentation includes some forward-looking statements. And why don't I start on slide 3?

We're beginning an exciting and defining year for SpringWorks as we transition into a commercial-stage oncology company. We expect to have two product launches by 2025, starting with nirogacestat, our gamma secretase inhibitor for patients with desmoid tumors later this year.

We're also developing mirdametinib, our MEK inhibitor for patients with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot